Abstract
Cancer is a serious health problem as a scientific challenge. A lot has been learned about the process of transformation of a normal cell into a tumor cell by studying genes and proteins that regulate this process either in cis or in trans. However, whether these molecular mechanisms succeed in fulfilling their potential to give a clinically evident disease depends in great measure on the host response to those molecular changes. The work of my laboratory aims to provide evidence in animal models as well as in cancer patients that immune system can control cancer growth and that this important function can be improved through vaccination with welldefined tumor antigens.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Finn OJ, Lotze MT: A decade in the life of tumor immunology. Clin Cancer Res 2001;7:759s-760s.
Finn OJ: Tumor-rejection antigens recognized by T lymphocytes. Curr Opin Immunol 1993;5:701–708.
Barnd DL, Lan MS, Metzgar RS, Finn OJ: Specific, major histocompatibility complex-unrestricted recognition of tumor-associated mucins by human cytotoxic T cells. Proc Natl Acad Sci USA 1989;86:7159–7163.
Finn OJ: Cancer vaccines: between the idea and the reality. Nat Rev Immunol 2003;3:630–641.
Graziano DF, Finn OJ: Tumor antigens and tumor antigen discovery. Cancer Treat Res 2004;123:89–111.
Kao H, Amoscato AA, Ciborowski P, Finn OJ: A new strategy for tumor antigen discovery based on in vitro priming of naive T cells with dendritic cells. Clin Cancer Res 2001;7:773s-780s.
Kao H, Marto JA, Hoffmann TK, et al: Identification of cyclin B1 as a shared human epithelial tumor-associated antigen recognized by T cells. J Exp Med 2001;194:1313–1323.
Vlad AM, Kettel JC, Alajez NM, Carlos CA, Finn OJ: MUC1 immunobiology: from discovery to clinical applications. Adv Immunol 2004;82:249–293.
Hiltbold EM, Vlad AM, Ciborowski P, Watkins SC, Finn OJ: The mechanisms of unresponsiveness to circulating tumor antigen MUC1 is a block in intracellular sorting and processing by dendritic cells. J Immunol 2000; 165:3730–3741.
Hiltbold EM, Ciborowski P, Finn OJ: Naturally processed class II epitope from the tumor antigen MUC1 primes human CD4+T cells. Cancer Res 1998;58:5066–5070.
Hiltbold EM, Alter MD, Ciborowski P, Finn OJ: Presentation of MUC1 tumor antigen by class I MHC and CTL function correlate with the glycosylation state of the protein taken Up by dendritic cells. Cell Immunol 1999;194:143–149.
Vlad AM, Muller S, Cudic M, et al: Complex carbohydrates are not removed during processing of glycoproteins by dendritic cells: processing of tumor antigen MUC1 glycopeptides for presentation to major histocompatibility complex class II-restricted T cells. J Exp Med 2002;196:1435–1446.
Soares MM, Mehta V, Finn OJ: Three different vaccines based on the 140-amino acid MUC1 peptide with seven tandemly repeated tumor-specific epitopes elicit distinct immune effector mechanisms in wild-type versus MUC1-transgenic mice with different potential for tumor rejection. J Immunol 2001;166:6555–6563.
Cramer DW, Titus-Ernstoff L, McKolanis JR, et al: Conditions associated with antibodies against the tumor-associated antigen MUC1 and their relationship to risk for ovarian cancer. Cancer Epidemiol Biomarkers Prev 2005;14:1125–1131.
Carlos CA, Dong HF, Howard OM, Oppenheim JJ, Hanisch FJ, Finn OJ: Human tumor antigen MUC1 is chemotactic for immature dendritic cells and elicits maturation but does not promote Th1 type immunity. J Immunol 2005;175:1628–1635.
Suzuki H, Graziano DF, McKolanis J, Finn OJ: T cell-dependent antibody responses against aberrantly expressed cyclin B1 protein in patients with cancer and premalignant disease. Clin Cancer Res 2005;11:1521–1526.
Yu M, Zhan Q, Finn OJ: Immune recognition of cyclin B1 as a tumor antigen is a result of its overexpression in human tumors that is caused by non-functional p53. Mol Immunol 2002;38:981–987.
Goydos JS, Elder E, Whiteside TL, Finn OJ, Lotze MT: A phase I trial of a synthetic mucin peptide vaccine. Induction of specific immune reactivity in patients with adenocarcinoma. J Surg Res 1996;63:298–304.
Ramanathan RK, Lee KM, McKolanis J, et al: Phase I study of a MUC1 vaccine composed of different doses of MUC1 peptide with SB-AS2 adjuvant in resected and locally advanced pancreatic cancer. Cancer Immunol Immunother 2005;54:254–264.
Schmielau J, Finn OJ: Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of t-cell function in advanced cancer patients. Cancer Res 2001;61:4756–4760.
Schmielau J, Nalesnik MA, Finn OJ: Suppressed T-cell receptor zeta chain expression and cytokine production in pancreatic cancer patients. Clin Cancer Res 2001; 7:933s-939s.
Finn OJ: Premalignant lesions as targets for cancer vaccines. J Exp Med 2003;198:1623–1626.
Finn OJ: Immune response as a biomarker for cancer detection and a lot more. N Engl J Med 2005;353:1288–1290.
Egloff AM, Weissfeld J, Land SR, Finn OJ: Evaluation of anticyclin b1 serum antibody as a diagnostic and prognostic biomarker for lung cancer. Ann N Y Acad Sci 2005;1062:29–40.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Finn, O.J. Human tumor antigens, immunosurveillance, and cancer vaccines. Immunol Res 36, 73–82 (2006). https://doi.org/10.1385/IR:36:1:73
Issue Date:
DOI: https://doi.org/10.1385/IR:36:1:73